Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results covered three months ended March 31, 2026.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results covered three months ended March 31, 2026
- Alkermes updated selected 2026 financial expectations through December 31, 2026
- Press release and investor presentation furnished as Exhibits 99.1 and 99.2
- Exhibits require review for earnings figures, guidance changes, and management outlook қиливатқан
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $392.9M, up from $306.5M, with proprietary sales reaching $338.1M
- LUMRYZ contributed $39.5M after February acquisition closing, adding commercial sleep-medicine exposure
- GAAP net loss $66.5M versus $22.5M income, reflecting Avadel transaction costs and higher operating expenses
- Adjusted EBITDA rose to $80.3M from $45.6M, but acquisition financing added $1.525B of term loans due 2031
- 2026 guidance maintained for revenue $1.73B–$1.84B and adjusted EBITDA $370M–$410M; GAAP net-loss range improved to $70M–$90M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.